Anti-angiogenic compositions and methods of use
View Patent ↗The present invention is directed to a stent comprising (a) a balloon expandable coronary stent; and (b) paclitaxel, in an amount that when tested in a chick chorioallantoic membrane assay is anti-angiogenic.
1. A stent comprising
(a) a balloon expandable coronary stent; and
(b) paclitaxel, in an amount that when tested in a chick chorioallantoic membrane assay is anti-angiogenic.
2. The stent of claim 1 , wherein the amount of paclitaxel is 5 micrograms.
3. A stent comprising
(a) a balloon expandable coronary stent; and
(b) paclitaxel or an analog thereof, in an amount that when tested in a chick chorioallantoic membrane assay is anti-angiogenic.
4. The stent of claim 3 , wherein the amount of paclitaxel or an analog thereof is 5 micrograms.
5. A stent comprising
(a) a balloon expandable coronary stent and
(b) a composition comprising paclitaxel,
wherein the composition when tested in a chick chorioallantoic membrane assay is anti-angiogenic.
6. A vascular stent comprising
an expandable stent; and
paclitaxel,
wherein the vascular stent contains paclitaxel in an effective amount which is capable of inhibiting angiogenesis in vivo.
7. The vascular stent of claim 6 , wherein the vascular stent is capable of inhibiting angiogenesis in a CAM assay.
8. The vascular stent of claim 6 , wherein the vascular stent is capable of inhibiting angiogenesis at a site of an angioplasty in a blood vessel.
9. A vascular stent prepared from components comprising:
(a) an expandable scaffold; and
(b) paclitaxel, in an amount that when tested in a chick chorioallantoic membrane assay is anti-angiogenic.
10. The vascular stent of claim 9 , wherein the vascular stent is capable of inhibiting angiogenesis in vivo.
11. The vascular stent of claim 10 , wherein the vascular stent is capable of inhibiting angiogenesis at a site of an angioplasty in a blood vessel.
12. The vascular stent of claim 10 , wherein the amount of paclitaxel is 5 micrograms.
13. A vascular stent prepared from components comprising:
(a) a balloon expandable scaffold; and
(b) a composition comprising paclitaxel,
wherein the composition when tested in a chick chorioallantoic membrane assay is anti-angiogenic.
14. The vascular stent of claim 13 , wherein the vascular stent is capable of inhibiting angiogenesis in vivo.
15. The vascular stent of claim 14 , wherein the vascular stent is capable of inhibiting angiogenesis at a site of an angioplasty in a blood vessel.
16. The stent of claim 1 , 3 , or 9 , wherein the amount of paclitaxel is 10 μg.
17. The stent of claim 1 , 3 , or 9 , wherein the amount of paclitaxel is 30 μg.